Photocure ASA (OSL:PHO)

Market Cap	1.68B +11.7%
Revenue (ttm)	671.85M +26.1%
Net Income	84.31M +3,843.5%
EPS	3.16 +3,895.6%
Shares Out	26.61M
PE Ratio	19.96
Forward PE	19.05
Dividend	n/a
Ex-Dividend Date	n/a

Volume	49,610
Average Volume	91,434
Open	63.00
Previous Close	63.10
Day's Range	62.00 - 63.50
52-Week Range	48.70 - 79.80
Beta	0.39
RSI	43.45
Earnings Date	Jul 29, 2026

About Photocure ASA

Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced cervical precancerous lesions. The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira; and a strategic agreemen...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1993
• Employees: 101
• Stock Exchange: Oslo Børs
• Ticker Symbol: PHO

Financial Performance

In 2025, Photocure ASA's revenue was 532.58 million, an increase of 1.37% compared to the previous year's 525.39 million. Losses were -1.52 million, -54.58% less than in 2024.